Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | TP53 | P04637 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | MC4R | P32245 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747226 | 0.93 | PAX8 (0.70) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3656790 | 0.92 | PAX8 (0.69) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL4749983 | 0.91 | PAX8 (0.68) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL4747164 | 0.91 | PAX8 (0.80) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL14042929 | 0.91 | PAX8 (0.68) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL4749256 | 0.91 | PAX8 (0.68) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3790489 | 0.90 | MAPT (0.71) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3791913 | 0.90 | PAX8 (0.69) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL4749363 | 0.90 | PAX8 (0.64) | PAX8MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL403648 | 0.89 | PAX8 (0.68) | PAX8MAPTTP53SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008119771-A2 | QUINOLINE-S-CARBOXYLIC ACID DERIVATIVES AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2008-10-09 | — | — | WO | claimed |
| EP-2432764-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | ClanoTech AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2008119771-A2 | QUINOLINE-S-CARBOXYLIC ACID DERIVATIVES AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119771-A2 | QUINOLINE-S-CARBOXYLIC ACID DERIVATIVES AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | FLT1, FLT4, VEGFA | PAX8 1573/4885MAPT 231/4885TP53 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.